Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702229 · ClinicalTrials.gov registry record · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 2 study of Gastric Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT05702229: Recruiting Phase 2 study of Gastric Cancer, sponsored by AstraZeneca.
NCT05702229 is a Phase 2 study of Gastric Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 163 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05702229, a Phase 2 study of Gastric Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Primary Outcome
the proportion of participants who have a confirmed complete response or confirmed partial response, as determined by the Investigator at local site per RECIST 1.1.
Conditions Studied
Interventions
- DRUG Rilvegostomig
- DRUG AZD0901
- DRUG Volrustomig
- DRUG FOLFOX
- DRUG XELOX
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Hangzhou
- Research Site - Hangzhou
- Research Site - Harbin
- Research Site - Hefei
- Research Site - Kunming
- Research Site - Wuhan
- Research Site - Yinchuan
- Research Site - Zhengzhou
New York
- Research Site - New Hyde Park
- Research Site - New York
- Research Site - New York
- Research Site - New York
- Research Site - Shirley
- Research Site - The Bronx
California
- Research Site - Los Angeles
- Research Site - Los Angeles
Louisiana
- Research Site - Baton Rouge
Michigan
- Research Site - Grand Rapids
Pennsylvania
- Research Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2029-05-31 |
| Phase | Phase 2 |
What NCT05702229 shows while recruiting
NCT05702229 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Rilvegostomig is the first listed.
NCT05702229 names 20 study sites across 6 states, led by Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT05702229 about?
NCT05702229 is a clinical study titled "Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma". This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
What is the current status of trial NCT05702229?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2023-01-16. Estimated completion is 2029-05-31.
What conditions does trial NCT05702229 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT05702229?
The interventions under investigation include: Rilvegostomig (DRUG), AZD0901 (DRUG), Volrustomig (DRUG), FOLFOX (DRUG), XELOX (DRUG).
Who is sponsoring clinical trial NCT05702229?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05702229 being conducted?
This trial has 20 study locations across California, Louisiana, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05702229's enrollment target sits among peer trials
163 58th of 153 higher than 95 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI